With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That’s not the same thing as paying to market drugs, but it’s hardly without controversy.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
A new research consortium spearheaded by the Indiana University School of Medicine and Eli Lilly and Co. could bring in $25 million to $50 million over five years to create a new approach for developing drugs that provide more precise treatment for small groups of patients.
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
United Way Worldwide President and CEO Brian Gallagher said John Lechleiter will help strengthen the not-for-profit network's capacity to meet growing human needs around the world.
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
